We are live on ! Find out more
GTBP icon

GT Biopharma

40 hedge funds and large institutions have $70.1M invested in GT Biopharma in 2021 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

6,938% more capital inflows, than outflows

Capital inflows: $55.8M | Capital outflows: $793K

625% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 4

167% more funds holding

Funds holding: 15 → 40 (+25)

133% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 3

18.66% more ownership

Funds ownership: 2.73% → 21.39% (+19%)

Holders
40
Holders Change
+25
Holders Change %
+166.67%
% of All Funds
0.69%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
29
Increased
7
Reduced
3
Closed
4
Calls
$9​K
Puts
–
Net Calls
+$9​K
Net Calls Change
+$9​K

GTBP Hedge Fund Activity: Q2 2021 in Review

40 of the 5,771 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q2 2021, worth a combined $70.1M — up 1,662% from $3.98M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new GTBP positions and 4 closed out — a net gain of 25 holders — while 7 added to existing stakes and 3 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $19.6M. The largest seller was Royal Bank of Canada, cutting an estimated $291K.

  • 40 institutional investors held GT Biopharma (GTBP) as of Q2 2021, up from 15 in Q1 2021.
  • Funds reported $70.1M of GT Biopharma stock for Q2 2021, up 1,662% quarter-over-quarter.
  • 29 funds opened new GT Biopharma positions in Q2 2021 and 4 closed out, a net change of +25 holders.
  • The largest GT Biopharma buyer in Q2 2021 was BlackRock, an estimated $19.6M added.
  • The largest GT Biopharma seller in Q2 2021 was Royal Bank of Canada, an estimated $291K sold.

Based on aggregated 13F filings for Q2 2021.